Skip to content
    LFCR
    Earnings call· Jun 2026(Q2 FY26)

    LIFECORE BIOMEDICAL, INC. \DE\ Q2 FY26 earnings call LFCR

    Aug 5, 2026 Source

    Executive summary

    Lifecore Biomedical Q2 FY26 — Strong Business Development Momentum and Reaffirmed Guidance

    Lifecore Biomedical reported a mixed Q2 FY26, with revenue and adjusted EBITDA declines, but reaffirmed its full-year guidance, citing strong business development momentum and a robust pipeline. The company successfully navigated numerous audits and added 6 new programs, including late-stage and commercial site transfers. Management highlighted significant SG&A reductions and improved liquidity, positioning the company for anticipated demand increases from its largest customer starting in 2027.

    Highlights

    5

    • Reaffirmed FY26 revenue guidance of $120M-$125M and adjusted EBITDA guidance of $20.5M-$25M.

    • Added 6 new programs to the pipeline in Q2, with 2 expected to generate commercial revenue in 2028-2029.

    • Successfully completed 7 audits/inspections (5 customer, 2 regulatory) with no material issues.

    • Achieved 5th consecutive quarter of period-over-period declines in SG&A and R&D expenses, totaling $16.2M since late 2024.

    • Improved liquidity to $38.8M, including $17.2M cash and $21.6M revolving credit availability.

    Concerns

    5

    • Q2 FY26 revenue decreased by $2.3M or 6.2% YoY to $34.2M.

    • Q2 FY26 adjusted EBITDA decreased by $0.5M to $8.6M.

    • Net loss for Q2 FY26 was $6.2M, or $0.19 per diluted share, compared to $1.1M ($0.06 per share) in prior year.

    • 6-month FY26 revenue decreased by $14.2M or 19.9% YoY to $57.4M.

    • 6-month FY26 net loss was $21.1M, or $0.61 per diluted share, compared to $15.9M ($0.48 per share) in prior year.

    Guidance & targets

    9
    CategoryTargetConfidence
    Total Revenue
    $120M-$125M
    high materiality
    High
    Adjusted EBITDA
    $20.5M-$25M
    high materiality
    High
    Revenue CAGR
    12%
    high materiality
    Medium
    Adjusted EBITDA Margin
    >25%
    high materiality
    Medium
    Fill/Finish Demand (Largest Customer)
    double
    high materiality
    High
    Fill/Finish Demand (Largest Customer)
    increase by >200%
    high materiality
    High
    Development Programs Commercialization
    11 programs
    medium materiality
    Medium
    SG&A Expenses (excluding one-time items)
    $6M per quarter range
    medium materiality
    High
    Free Cash Flow Generation
    $7M-$10M
    medium materiality
    Medium

    Operational metrics

    17
    Revenue decrease
    $2.3MYoY
    Q2 FY26

    Decrease compared to Q2 FY25.

    SG&A expense decrease
    $1MYoY
    Q2 FY26

    Decrease compared to Q2 FY25.

    Adjusted EBITDA
    $8.6Mdecreased by $0.5M
    Q2 FY26

    Compared to $9.1M in Q2 FY25.

    Revenue decrease
    $14.2MYoY
    6M FY26

    Decrease compared to 6M FY25.

    Gross profit decrease
    $7.3MYoY
    6M FY26

    Decrease compared to 6M FY25.

    SG&A expense decrease
    $3.2MYoY
    6M FY26

    Decrease compared to 6M FY25.

    Adjusted EBITDA
    $9.6Mdecreased by $5.1M
    6M FY26

    Compared to $14.8M in 6M FY25.

    Cumulative SG&A and R&D reductions
    $16.2M
    since late 2024

    Total reductions achieved through efficiency initiatives.

    Liquidity
    $38.8Mimproved significantly since late 2024
    Q2 FY26 end

    Includes cash and revolving credit availability.

    Capacity utilization
    60%
    2029

    Projected utilization based on current growth plans, with headroom for further growth.

    FDA warning letters (industry-wide)
    up ~50%
    YoY

    Increased enforcement actions driving customers to high-quality CDMOs like Lifecore.

    Injectables in drug development pipeline
    50%
    current

    Strong tailwind for the company's market.

    New programs added
    6
    Q2 FY26

    Includes a combination of existing and new customers, ranging from preclinical to commercial transfers.

    New business wins
    9
    YTD

    Total new business wins year-to-date.

    New business wins
    13
    last 12 months

    Total new business wins over the past year.

    Late-stage/commercial site transfer opportunities
    >60%
    since mid-last year

    Percentage of opportunities competed on that are derisked from clinical approval.

    Debt service payment method
    —
    Q2 FY26

    Began paying a portion of debt service in cash as opposed to payment-in-kind, viewed as a milestone reflecting improving free cash flow.

    Industry KPIs

    1
    MetricValueDetails
    Revenue EPS guidanceRevenue $120M-$125M; Adjusted EBITDA $20.5M-$25MUSD

    Deals & partnerships

    3
    Largest customerContractually committed fill/finish demand increase

    Working closely with the largest customer to support a significant increase in demand, including entering new markets like Japan after a successful PMDA inspection.

    Existing and new customersAddition of new programs to pipeline

    Added 6 new programs to the pipeline in Q2, ranging in scope from preclinical to the commercial transfer of 2 currently marketed products. Three signed in June alone.

    Specialty biopharmaceutical companyNew late-stage injectable program

    Closed an additional late-stage injectable program since the end of the quarter.

    Risks & headwinds

    5
    Timing, mix, and volume of other customersQ2 FY26 and 6 months ended June 30, 2026

    Decreased revenues in Q2 FY26 and 6M FY26

    Mitigation: Expect a step-up in CDMO revenues in the back half of the year, including higher aseptic and development revenues.

    Unfavorable manufacturing costsQ2 FY26 and 6 months ended June 30, 2026

    Decreased gross profit in Q2 FY26 and 6M FY26

    Mitigation: Cost reduction activities and efficiency projects are underway to positively impact margins.

    Contractual take-or-pay arrangement in prior periodQ2 FY26 and 6 months ended June 30, 2026

    Impacted Q2 FY26 and 6M FY26 revenues and gross profit negatively compared to prior year

    Legacy legal mattersPrior periods

    Nonrecurring expenses impacted SG&A in prior periods

    Mitigation: Reduction in nonrecurring expenses related to legacy legal matters contributed to SG&A decrease.

    Preferred stock payment obligationDecember 28

    Potential payment due December 28; unpaid amounts accrue 1% interest per month

    Mitigation: Payment would require approval under credit agreements; company aims to retain enough cash for debt compliance and future growth.

    What to watch in Q3 FY26

    5

    Alcon demand ramp-up

    early 2027
    CurrentCommitted demand expected to double beginning 2027
    TargetInitial signs of increased demand in early 2027

    Why it matters

    This is a significant inflection point for revenue and capacity utilization, crucial for mid-term growth.

    Contractually committed fill/finish demand is expected to double beginning in 2027 with committed demand increasing by more than 200% in 2028 as compared to 2026.

    Q&A highlights

    6

    When will the expected demand inflection from the largest customer (Alcon) begin in 2027, and will it be immediate or ramped?

    The ramp-up will start earlier in 2027, with a slightly heavier weighting towards the back end of the year.

    “I would say that it is -- there's -- it starts earlier in '26, I would say, with a slightly heavier weighting on the back end of '27 -- excuse me. So starting early in '27 with a heavier weighting on the back end.”

    asked by Matthew Hewitt · answered by Paul Josephs

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Pillars Driving Growth

    Lifecore is actively executing its three-pillar growth strategy: maximizing existing commercial business, advancing its development pipeline, and adding new programs through business development. This focused approach is designed to deliver durable medium- to long-term growth and enhance shareholder value. The company's progress across these pillars underpins its confidence in reaffirming full-year 2026 guidance.

    02

    Significant Customer Demand Inflection

    The company anticipates a substantial increase in demand from its largest customer, with contractually committed fill/finish demand projected to double in 2027 and grow by over 200% in 2028 compared to 2026 levels. This expansion includes entry into new international markets, such as Japan, following a successful and rigorous inspection by the Japanese PMDA, marking a critical step for future product availability.

    03

    Robust Pipeline and Business Development Success

    Lifecore added 6 new programs to its pipeline in Q2, with 2 expected to generate commercial revenue by 2028-2029. The late-stage pipeline comprises 11 existing development programs with commercialization potential by the end of 2028. The company's revamped business development team has secured 9 new business wins year-to-date and 13 over the last 12 months, with over 60% of recent opportunities being late-stage or commercial site transfers.

    04

    Operational Efficiency and Margin Expansion

    The company has achieved its fifth consecutive quarter of period-over-period declines in SG&A and R&D expenses, resulting in cumulative reductions of $16.2 million since late 2024. Management is progressing over 40 projects aimed at further cost reductions and productivity improvements, targeting an adjusted EBITDA margin exceeding 25% by 2029. SG&A expenses (excluding one-time items📎) are expected to trend towards $6 million per quarter in the second half of 2026.

    05

    Favorable Market Dynamics and Quality Focus

    Lifecore is benefiting from industry tailwinds, including increased FDA enforcement actions (warning letters up ~50% YoY) against other contract manufacturers and the ongoing trend of regionalized drug manufacturing in the US. These factors drive demand for high-quality, technically capable CDMOs. The company successfully completed 7 audits and inspections in Q2 with no material issues, underscoring its commitment to quality and compliance.

    AI-generated summary of the company’s earnings call. Not investment advice.